Tag: Androgen Deprivation Therapy

Surgery or radiotherapy: Treatment decision for high-risk PCa

Due to the absence of randomized data clearly showing a superiority of one treatment option over the others in terms of classical survival endpoints, patients diagnosed with High-Risk Prostate Cancer (HRPCa) are currently basing their choice mostly on individual...

Do we need to continue androgen deprivation therapy?

Fortunately, a growing number of treatment options exist to treat metastatic castrate-resistant prostate cancer (mCRPC); however, with these newer options many questions about optimising treatment remain unanswered. There is an on-going discussion on the value and need of androgen...

Where do we stand with predictive biomarkers in mCRPC?

Treatment options for men with metastatic castrationresistant prostate cancer (mCRPC) have expanded with the introduction of several new approved agents including abiraterone, enzalutamide, cabazitaxel and radium-2231-6. With evidence that both abiraterone acetate and enzalutamide are effective agents when administered...